Known targets — ChEMBL curated mechanism
APH1AAPH1BNCSTNPSEN1PSEN2PSENEN
The experimentally established mechanism targets of Avagacestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 known ✓ | P49810 | 20/20 | 1.00 |
| ▸ | APH1B known ✓ | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN known ✓ | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A known ✓ | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avagacestat SCHEMBL381851 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL29392347 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11939689 | 0.93 | PSEN1 (0.87) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL12227575 | 0.92 | PSEN1 (0.85) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1464859 | 0.87 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1464862 | 0.87 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL638589 | 0.86 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7871814 | 0.86 | PSEN1 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21730165 | 0.86 | PSEN1 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1507913 | 0.84 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4735585-A1 | ENHANCING NEURONAL DIFFERENTIATION OF NEURAL PROGENITOR CELLS | Novo Nordisk A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| US-12599587-B2 | Chlorinated tetralin compounds and pharmaceutical compositions | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | OSPEDALE PEDIATRICO BAMBINO GESU (IT) | 2026-03-05 | — | — | US | claimed |
| US-20260043007-A1 | METHOD FOR PRODUCING CARDIAC MUSCLES | KYOTO UNIVERSITY (JP) | 2026-02-12 | — | — | US | claimed |
| US-20260034099-A1 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | SPRINGWORKS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | claimed |
| US-20260027084-A1 | TREATMENT OF MULTIPLE MYELOMA | SPRINGWORKS THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260002124-A1 | ENHANCING NEURONAL DIFFERENTIATION OF VENTRAL MIDBRAIN NEURAL PROGENITOR CELLS | NOVO NORDISK AS (DK) | 2026-01-01 | — | — | US | claimed |
| US-20250340837-A1 | CELLS | UNIVERSITY OF GENEVA (CH) | 2025-11-06 | — | — | US | claimed |
| US-8084477-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | claimed |
| EP-2205575-B1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2011-03-16 | — | — | EP | claimed |
| WO-2010120662-A2 | BIOAVAILABLE COMPOSITIONS OF AMORPHOUS ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | claimed |
| WO-2010120755-A1 | BIOAVAILABLE CAPSULE COMPOSITIONS OF AMORPHOUS ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | claimed |
| US-20100260837-A1 | Bioavailable Capsule Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | claimed |
| US-20100261768-A1 | Bioavailable Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | claimed |
| EP-2205575-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2010-07-14 | — | — | EP | claimed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | claimed |
| WO-2009058552-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | PSEN1 5/4885PSEN2 8/4885APH1B 9/4885 |
| US-20260002124-A1 | ENHANCING NEURONAL DIFFERENTIATION OF VENTRAL MIDBRAIN NEURAL PROGENITOR CELLS | L1CAM, NES, NOTCH1 | PSEN1 256/4885PSEN2 195/4885APH1B 1644/4885 |
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | BACE1, BACE2, PSENEN | PSEN1 11/4885PSEN2 28/4885APH1B 102/4885 |
| US-20260034099-A1 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | BACE1, BACE2, DSG1 | PSEN1 11/4885PSEN2 16/4885APH1B 89/4885 |
| US-20100260837-A1 | Bioavailable Capsule Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound | SLC46A1, SUCNR1, SDHA | PSEN1 1467/4885PSEN2 531/4885APH1B 1397/4885 |
| US-12599587-B2 | Chlorinated tetralin compounds and pharmaceutical compositions | CLIC1, CLCN2, CSNK1D | PSEN1 464/4885PSEN2 447/4885APH1B 3750/4885 |
| US-20260027084-A1 | TREATMENT OF MULTIPLE MYELOMA | BACE1, BACE2, CD47 | PSEN1 150/4885PSEN2 505/4885APH1B 39/4885 |
| US-20260043007-A1 | METHOD FOR PRODUCING CARDIAC MUSCLES | NOTCH1, NOTCH4, NOTCH3 | PSEN1 144/4885PSEN2 402/4885APH1B 10/4885 |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, APBA1 | PSEN1 4/4885PSEN2 9/4885APH1B 6/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | PSEN1 3727/4885PSEN2 4120/4885APH1B 630/4885 |
| US-20100261768-A1 | Bioavailable Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound | SI, SUCLA2, SUCNR1 | PSEN1 2365/4885PSEN2 1534/4885APH1B 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.